Gv Prasad

Dr. Reddy’s plans to invest Rs 700 crore into capacity expansion of biosimilars and Active Pharmaceutical Ingredients. GV Prasad, Co-chairman and Managing Director of Dr. Reddy Laboratories shares his insights on future investments and artificial intelligence. We have seen how AI has reduced the amount of experimentation we need to do, bring more precision to our work, and give us ideas that normal human beings wouldn’t have thought about, he said while explaining how they are using machine learning to understand scaleups. For information watch this interview.

Dr Reddy's Q2 profit sinks 60%, US & EMs biz drag revenue 10%

Pharma major Dr Reddy's Laboratories' second quarter consolidated net profit plunged 60.1 percent year-on-year to Rs 309 crore on weak operational performance but sequentially doubled.

New launches to drive growth in second quarter: Dr Reddy's

There are approvals pending, but not from its Srikakulam plant. But improving quality checks at pharma's plants would be a high priority, says GV Prasad, CEO, Dr Reddy‘s.

Will resolve issues raised by USFDA in a timely manner: DRL

The drug major had received a warning letter on November 5, 2015 from the USFDA regarding deviations from current good manufacturing practices (CGMP) at its active pharmaceutical ingredient (API) facilities at Srikakulam, Andhra Pradesh and Miryalaguda in Telangana

Dr Reddy's gets FDA warning letter for three drug plants

The warning letter was issued by the FDA to Dr Reddy's on Thursday for its Srikakulam, Miryalaguda and Duvvada drug manufacturing plants - all based in southern India.

Plan to revamp systems as per FDA expectations: Dr Reddy's

Speaking on acquisitions, Satish Reddy, Chairman of Dr Reddy's said they are always on the lookout for strategic fits to boost growth.

Dr Reddy's Q1 net up 14% at Rs 626 cr led by US & India biz

Total income, during the quarter, rose to Rs 3,758 crore up 7 percent from Rs 3,517.5 crore year-on-year. It earned forex gain of Rs 1.2 crore in Q1FY16 against Rs 47.6 crore (Y-o-Y).

See growth over base of last year: Dr Reddy's CEO

Dr Reddy's Labs has posted a consolidated net profit of Rs 519 crore in the quarter ended March 2015 up 7.8 percent from Rs 481.6 crore in the corresponding quarter last fiscal. During the period, total income was up 11.2 percent at Rs 3870 crore versus Rs 3481 crore (Y-o-Y) on consolidated basis.

Dr Reddy's up 2% on pact with Hetero for Hepatitis drug

Shares of Dr Reddy's Laboratories gained 1.7 percent intraday Tuesday on agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

Core generics, API biz to drive FY16 growth: Dr Reddy's

GV Prasad, Co-Chairman & CEO of Dr Reddy‘s Laboratories said a lot of growth is seen in emerging markets

Likely to file 2 NDAs worth $100 m each soon: Dr Reddy's

Discussing the company‘s results, GV Prasad co-chairman and CEO, DRL, said the quarter has been a flattish one on the back of high R&D expenses. He expects growth to return once launches start happening.

BioAsia 2014: A holistic approach to product innovation

Companies from across the globe come together to pull in ideas and resources for sustainable and viable biotech innovations. It may sound technical, but CNBC-TV18 learnt that it is very relevant to our growing healthcare needs.

Delay in clinical trials approval affecting pharma sector

Launching a new drug in India, whether a completely new molecule or a generic one, has become a herculean task. The Supreme Court's recent dictat that the government review 157 clinical trials has delayed fresh approvals.

GV Prasad: You cannot have a company driven by one person

Dr Reddy‘s Laboratories' GV Prasad says that an organisation must be able to sustain changing ownership, technologies, products and strategies

Dr Reddy's Lab appoints GV Prasad as chairman

Pharma company Dr Reddy's Laboratories Ltd Monday said it has appointed GV Prasad as chairman and CEO, and Satish Reddy as cice chairman.

Dr Reddy's Labs to acquire OctoPlus NV for euro 27.4m

Drug maker Dr Reddy's Laboratories today said it has decided to acquire Netherlands-based OctoPlus NV, a speciality pharmaceutical company, for about 27.4 million euros (about Rs 193 crore).

Growth rates may decline in next few years: Dr Reddy's

Country's second largest drug maker Dr Reddy's Laboratories today said its growth rates are likely to decline in the next few years due to expiry of many of its patents.

Dr Reddy's gets USFDA ok for deep vein thrombosis injection

Dr Reddy’s Laboratories has received final approval from the US Food and Drugs Administration (FDA) to sell Fondaparinux Sodium injection, which is used for the treatment and prevention of deep vein thrombosis (DVT).

Union Budget 2011: India Inc assesses the math

In an interview with CNBC-TV18's Menaka Doshi, an illustrious panel of business leaders including Chanda Kochhar, MD and CEO, ICICI Bank, Harsh Mariwala, CMD, Marico, Baba Kalyani, CMD, Bharat Forge, GV Prasad, Dr Reddy's and YM Deosthalee, Whole-Time Director and CFO, L&T, assess the math of the budget.

Unsure of how biz will shape up in German mkt: Dr Reddy's

Speaking to CNBC-TV18 on the quarter gone by, GV Prasad, Vice Chairman & CEO, Dr Reddy Laboratories said operating expenses have increased due to one-time litigation costs.